Posts

Welcome to the Fritsma Factor, please join our hemostasis discussions.

Congratulations to Drs. Emmanuel Favaloro and Guiseppe Lippi for their 2017 Humana Press...
Aug 20, 2017 10:29am
Although the FDA approved CSL-Behring's RiaSTAP, human plasma-derived fibrinogen concentrate in...
Aug 17, 2017 1:22pm
Odetta Hanna from Sekisui Diagnostics asked, "Do you have a good resource to obtain the medical...
Aug 17, 2017 9:20am
From Sharon Johnson, Sysmex America: Hi George: I was recently asked if guidelines or clinical...
Aug 12, 2017 10:35am
Aug 20, 2017 10:29am
Congratulations to Drs. Emmanuel Favaloro and Guiseppe Lippi for their 2017 Humana Press publication, "Hemostasis and Thrombosis: Methods and Protocols." Among other attributes, the text is a practical manual that provides laboratory assay principles and detailed protocols.
0 Comments
Aug 17, 2017 1:22pm
Although the FDA approved CSL-Behring's RiaSTAP, human plasma-derived fibrinogen concentrate in 2009, it seems most facilities continue to use cryoprecipitate to treat hypofibinogenemia, dysfibrinogenemia, and afibrinogenemia. Has your institution switched to RiaSTAP? Why, or why not?
1 Comment
Aug 17, 2017 9:20am
Odetta Hanna from Sekisui Diagnostics asked, "Do you have a good resource to obtain the medical decision points for coagulation assays?"
1 Comment
Aug 12, 2017 10:35am
From Sharon Johnson, Sysmex America: Hi George: I was recently asked if guidelines or clinical recommendations had changed for VWF normal ranges based on blood group. In CLSI Guideline H-51A. 2002, it suggests laboratories establish their own reference ranges for VWF for “O” and “Non-O” blood groups, as patients with group “O” typically have much lower normal values. Is there another or newer clinical guideline from ISTH or another hemostasis group that supports one reference range for all blood groups?  I’d appreciate insights from your readers and contributors on this subject.
0 Comments